[CAS NO. 1234480-50-2] XMD8-92

Name: XMD8-92
Brand: Arctom Scientific
SKU: SLK-S7525

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1234480-50-2]

Store

Catalog

SLK-S7525

Brand

Selleck

CAS

1234480-50-2

DESCRIPTION [1234480-50-2]

Overview

MDL	MFCD18782742
Molecular Weight	474.55
Molecular Formula	C26H30N6O3
SMILES	O=C1C2=CC=CC=C2N(C)C3=NC(NC4=CC=C(N5CCC(O)CC5)C=C4OCC)=NC=C3N1C

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	2.1073 mL	10.5363 mL	21.0726 mL
5 mM	0.4215 mL	2.1073 mL	4.2145 mL
10 mM	0.2107 mL	1.0536 mL	2.1073 mL
50 mM	0.0421 mL	0.2107 mL	0.4215 mL

Description

XMD8-92 is a potent and selective dual inhibitor of and with of 80 nM and 170 nM for ERK5 and BRD4(1), respectively.

Targets

BMK1 ^[1] (Cell-free assay)	BRD4 (1) ^[4] (Cell-free assay)
80 nM(Kd)	170 nM(Kd)

In vitro

XMD8-92, via inhibition of BMK1 activation, significantly induces p21 expression in cells, and mediates suppression of cancer cell proliferation. XMD8-92 markedly abrogates the inhibitive effects of hydroxysafflor yellow A (HSYA) on hepatic stellate cell (HSC) activation, and blockes the HSYA-mediated MEF2C down-regulation.

References

[1] Yang Q, et al. Cancer Cell. 2010, 18(3), 258-267.
[2] Dong H, et al. Pharm Biol. 2013. doi:10.3109/13880209.
[3] Sureban SM, et al. Cancer Lett. 2014 , 351(1), 151-161.
[4] Emme C K Lin, et al. Proc Natl Acad Sci U S A . 2016 Oct 18;113(42):11865-11870.
[5] Duy Nguyen, et al. J Med Chem . 2019 Jan 24;62(2):928-940.